Rising Pharma Holding, Inc. recalls
Rising Pharma Holding, Inc. is named on 9 recalls in Recall Relay's records since November 2023, from FDA (13 recalled products: FDA lists each product as its own recall); the most recent was July 13, 2026.
All 13 recalled products, newest first.
-
Class IIofficial
Rising Pharma Holding, Inc. recalls RisingPresence of Precipitate: medication was crystallizing and particles floating in the bottle
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Product label: Temozolomide CapsulesFailed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
-
Class IIofficial
Rising Pharma Holding, Inc. recalls CarbidopaProduct mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP 20 mgCGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine DR Capsules USP 60 mgCGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP 30 mgCGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
-
Class IIofficial
Rising Pharma Holding, Inc. recalls Duloxetine DR Capsules USP 60 mgCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
-
Class IIIofficial
Rising Pharma Holding, Inc. recalls Diflorasone Diacetate OintmentFailed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.
-
Class IIIofficial
Rising Pharma Holding, Inc. recalls Pregabalin Capsules 50mgPresence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles during packaging set up. Tablet identified as pantoprazole tablet 20mg.
-
Class IIofficial
Rising Pharma Holding, Inc. recalls buPROPion Hydrochloride Extended-Release TabletsPresence of Foreign Tablets/Capsules
This page groups recalls by the company name the agency printed, so it can include different companies with similar names, and a recall may name a store or distributor rather than the maker. It counts the recalls in Recall Relay's records, not a company's whole history; an FDA recall that lists several products counts once. Open a recall to see its details and the agency's official notice, which is always the final word. Recall Relay isn't affiliated with any agency or with the companies named here.
Severity labels say where they come from: “official” is the agency's own class, “advisory” is based on the agency's safety warning, and “est. risk” is Recall Relay's estimate from the hazard description, not an agency classification.
Hear about the next one
Recall Relay can email you when a new recall mentions Rising Pharma Holding, Inc. or any words you choose. Start with a free key (no card needed), then set up alerts on your account page.
Get recall alerts